Harvard Bioscience, Inc.
HBIO
$0.76
$0.011.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.60% | -12.24% | -14.41% | -16.14% | -13.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.60% | -12.24% | -14.41% | -16.14% | -13.15% |
| Cost of Revenue | -6.83% | -8.50% | -10.90% | -14.25% | -11.31% |
| Gross Profit | -13.25% | -14.87% | -16.87% | -17.45% | -14.39% |
| SG&A Expenses | -15.60% | -13.53% | -9.44% | -6.63% | -4.19% |
| Depreciation & Amortization | -17.66% | -9.22% | -7.09% | -4.89% | -6.64% |
| Other Operating Expenses | -79.12% | -79.12% | -97.52% | -- | -- |
| Total Operating Expenses | -13.26% | -12.27% | -11.44% | -9.50% | -6.31% |
| Operating Income | 67.70% | 13.07% | -195.69% | -307.94% | -252.25% |
| Income Before Tax | -301.20% | -503.98% | -602.98% | -356.38% | -469.64% |
| Income Tax Expenses | -72.48% | -63.41% | -84.30% | -13.85% | -3.81% |
| Earnings from Continuing Operations | -278.03% | -437.61% | -564.88% | -263.25% | -336.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -278.03% | -437.61% | -564.88% | -263.25% | -336.44% |
| EBIT | 67.70% | 13.07% | -195.69% | -307.94% | -252.25% |
| EBITDA | 99.83% | 7.37% | -54.79% | -79.26% | -76.63% |
| EPS Basic | -271.82% | -427.24% | -549.88% | -256.95% | -326.79% |
| Normalized Basic EPS | 51.27% | -7.10% | -21.86% | -190.37% | -544.69% |
| EPS Diluted | -270.52% | -421.33% | -541.03% | -234.89% | -299.03% |
| Normalized Diluted EPS | 51.13% | -7.29% | -22.05% | -189.54% | -539.04% |
| Average Basic Shares Outstanding | 1.96% | 1.97% | 2.16% | 2.53% | 2.33% |
| Average Diluted Shares Outstanding | 2.42% | 2.43% | 2.63% | 2.59% | 1.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |